60 Degrees Pharmaceuticals (SXTP) Return on Equity (2023 - 2025)
Historic Return on Equity for 60 Degrees Pharmaceuticals (SXTP) over the last 3 years, with Q3 2025 value amounting to 2.35%.
- 60 Degrees Pharmaceuticals' Return on Equity fell 5700.0% to 2.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.35%, marking a year-over-year decrease of 5700.0%. This contributed to the annual value of 1.8% for FY2024, which is 22000.0% down from last year.
- According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' Return on Equity is 2.35%, which was down 5700.0% from 2.45% recorded in Q2 2025.
- 60 Degrees Pharmaceuticals' Return on Equity's 5-year high stood at 0.39% during Q2 2023, with a 5-year trough of 2.54% in Q1 2025.
- Its 3-year average for Return on Equity is 0.98%, with a median of 0.67% in 2023.
- Per our database at Business Quant, 60 Degrees Pharmaceuticals' Return on Equity tumbled by -4800bps in 2024 and then plummeted by -24100bps in 2025.
- Over the past 3 years, 60 Degrees Pharmaceuticals' Return on Equity (Quarter) stood at 0.67% in 2023, then plummeted by -136bps to 1.59% in 2024, then plummeted by -48bps to 2.35% in 2025.
- Its Return on Equity stands at 2.35% for Q3 2025, versus 2.45% for Q2 2025 and 2.54% for Q1 2025.